Mark Anthony McCamish

Mark Anthony McCamish (board member) discloses dealings in 3 companies, chiefly Forty Seven, Inc., Avadel Pharmaceuticals PLC and Rafael Holdings, Inc. Between 26 December 2018 and 12 February 2026, the trades on record add up to 41 filings.

Both buying and selling appear: 2 purchases worth €834k, against 15 sales worth €5.7M. The net balance comes to €4.9M on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 5 share grants and 15 option exercises.

The record was last updated on 12 February 2026 with a transaction (€389k) in Avadel Pharmaceuticals PLC. The clock since the last published purchase (18 September 2020) now reads 2,224 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.